PBA
VIR icon

Paradigm Biocapital Advisors’s Vir Biotechnology VIR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,014,239
Closed -$24.9M – 35
2023
Q2 		$24.9M Buy
+1,014,239
New +$25.5M 1.92% 21

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paradigm Biocapital Advisors's VIR Position: Q3 2023 in Review

Paradigm Biocapital Advisors sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 1,014,239 shares — an estimated $24.9M sold.

Paradigm Biocapital Advisors first reported a position in VIR in Q2 2023 and held it in 1 quarter. The position peaked at $24.9M in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Paradigm Biocapital Advisors reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,014,239 Vir Biotechnology shares in Q3 2023, an estimated $24.9M.
  • Paradigm Biocapital Advisors first reported a position in Vir Biotechnology in Q2 2023 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Vir Biotechnology position peaked at $24.9M in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.